“This approval is the result of the vision and tenacity of our entire Lamassu team and our partners,” said Dr. Gabi Hanna, CEO of Lamassu. “It is a critical step to move beyond conventional chemotherapy to targeted therapy to bring hope and healing to millions who suffer from stubborn cancers that don’t respond to conventional treatments and to reduce the toxicity of cancer treatments. With SA53-OS patented in 69 countries, successful trials could make a significant impact on the global fight against cancer.”